Beijing Northland Biotechnology Co., Ltd. is an innovative biopharmaceutical enterprise specializing in the research, development, production and sales of gene therapy drugs, recombinant protein drugs and ophthalmic medications.  Founded in June 2004 and listed on the Beijing Stock Exchange in November 2021 with stock code 920047. Northland-bio is recognized as the Key High-tech Enterprise of the National Torch Program, a Beijing-based scientific research and development institution, the Beijing Engineering Technology Research Center for Naked Plasmid Gene Therapy Drugs, a Beijing-based international science and technology cooperation base, a G20 innovation-leading enterprise in Beijing's biomedical industry, and Beijing "Specialized, Refined, Characteristic, and Innovative" SMEs.

The company boasts a highly qualified R&D and management team with extensive experience in preclinical research, clinical studies, production and quality management, pharmaceutical plant construction and drug distribution. The company has established core technology platforms covering gene vector construction, engineered microbial strain development, microbial expression, mammalian cell expression, biopharmaceutical manufacturing processes and their scale-up technologies, as well as ophthalmic drop formulation development—providing a solid foundation for the continuous advancement of its pipeline projects. Guided by clinical needs and leveraging its proprietary core technology platforms, the company is primarily dedicated to the research, development  and industrialization of innovative bioengineered drugs in areas such as cardiovascular diseases, metabolic disorders, rare diseases and ophthalmic conditions.

The company boasts an extensive and highly mature drug R&D pipeline. Currently, it is developing 11 innovative bioengineered drugs targeting 13 different indications, three of which have already entered the clinical research stage. Among these, the recombinant human hepatocyte growth factor naked plasmid injection (NL003) has completed Phase III clinical trials and has been submitted for New Drug Application (NDA); the recombinant human interleukin-11 injection ( NL002) has entered Phase III clinical trials; and the recombinant human thymosin β4 injection ( NL005) is currently undergoing Phase II clinical trials. Several ophthalmic drug candidates are being developed and launched. The company holds 22 authorized patents and has successively undertaken 8 national-level  projects.

While adhering to independent R&D, the company has established long-term, stable partnerships with pharmaceutical research institutions both at home and abroad. Through various collaboration models—including joint R&D and technology transfer—the company closely tracks international trends and developments in biotechnology, ensuring its technological edge in drug development and compliance with global standards. In 2012, the company formed a joint venture with Huons, a well-known Korean pharmaceutical company, to establish Beijing Huonland Pharmaceutical Co., Ltd. which introducing an advanced BFS system and specializing in the production of high-quality ophthalmic drugs. Currently, Huonland is capable of manufacturing both single-dose and multi-dose eye drops, with an annual production capacity of 260 million units. At the same time, it offers CMO/CDMO services, providing customers with integrated solutions for the design, R&D and manufacturing of ophthalmic products.

Guided by the principle of “Create Value, Serve Health,” Northland is committed to becoming a leading enterprise in China’s gene therapy sector and making positive contributions to the advancement of China’s pharmaceutical industry and human health!